Trending...
- Value Add Industrial Investor Closes on Speculative Financing for the Acquisition of 67,000SF Vacant Warehouse in Montgomery County, PA
- TVS Music Network.Com to Produce 26 More Episodes of Senior Prom in their Philadelphia Studio
- New Comcast Report Finds Consumers Vastly Underestimate How Often Home Networks Are Targeted by Cyber Threats
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Evolus, Inc. ("Evolus" or the "Company") (NASDAQ: EOLS) securities between February 1, 2019 and July 6, 2020, inclusive (the "Class Period"). Evolus investors have until December 15, 2020 to file a lead plaintiff motion.
Investors suffering losses on their Evolus investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On July 6, 2020, the U.S. International Trade Commission ("ITC") issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau™. The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture. As a result, the ITC Judge recommended a ten-year long ban on Evolus' ability to import Jeuveau™ into the United States and a ten-year long cease and desist order preventing Evolus from selling Jeuveau™ in the United States.
More on The PennZone
On this news, Evolus' share price declined dramatically, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020, thereby injuring investors.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the actual source of botulinum toxin bacterial strain, along with the manufacturing processes used to develop Jeuveau, originated with and were misappropriated from Medytox; (2) that adequate evidentiary support existed for the allegations that the Company misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau; (3) as a result, Evolus faced a actual danger of regulatory and/or court action, ceasing the import, marketing, and sale of Jeuveau; (4) which in turn jeopardized the Company's ability to commercialize Jeuveau in the United States and generate revenue; and (5) that any revenues generated from the sale of Jeuveau were based on Evolus' unlawful actions, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox; and (6) that, as a result, the Company's public statements were materially false and misleading at all relevant times.
More on The PennZone
If you purchased Evolus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Investors suffering losses on their Evolus investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
On July 6, 2020, the U.S. International Trade Commission ("ITC") issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau™. The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture. As a result, the ITC Judge recommended a ten-year long ban on Evolus' ability to import Jeuveau™ into the United States and a ten-year long cease and desist order preventing Evolus from selling Jeuveau™ in the United States.
More on The PennZone
- Pennsylvania: Gov. Wolf Sends Letter Urging Congress to Extend Federal Programs for Unemployed Workers
- Fellini In Action, 8 1/2 Set Photography by Paul Ronald Exhibit
- PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels
- Bells & Balls in the Bottoms Ring In Kansas City's West Bottoms Holiday Weekends
- Foundation Offers FREE Workshop To Motivate Black Male Students After Tumultuous 2020
On this news, Evolus' share price declined dramatically, falling 37% over the course of two trading days, to close at $3.35 on July 8, 2020, thereby injuring investors.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the actual source of botulinum toxin bacterial strain, along with the manufacturing processes used to develop Jeuveau, originated with and were misappropriated from Medytox; (2) that adequate evidentiary support existed for the allegations that the Company misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau; (3) as a result, Evolus faced a actual danger of regulatory and/or court action, ceasing the import, marketing, and sale of Jeuveau; (4) which in turn jeopardized the Company's ability to commercialize Jeuveau in the United States and generate revenue; and (5) that any revenues generated from the sale of Jeuveau were based on Evolus' unlawful actions, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox; and (6) that, as a result, the Company's public statements were materially false and misleading at all relevant times.
More on The PennZone
- Demo Day: 11 Startups Present Innovations, Partnership Deals Following Comcast NBCUniversal LIFT Labs Accelerator, powered by Techstars
- Pennsylvania: Governor Wolf Announces Life Sciences Partnership to Create Jobs, Develop COVID-19 Vaccine
- Olympus Partners with COPD Foundation to Serve Emphysema Patient Community
- Comcast Announces $1 Million Commitment to Per Scholas to Combat the Tech Opportunity Gap Across the U.S.
- Davlyn Group Acquires Norfab-Amatex
If you purchased Evolus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Filed Under: Business
0 Comments
Latest on The PennZone
- National Cannabis Risk Management Association Enhances Its Marketing And Membership Strategies With New Additions To The Team
- Connect America Partners with Idaho Health Data Exchange to Deliver Telehealth Solutions to Patients Statewide
- 'Bounce Back to Success' hits Amazon Best-Seller List
- Evoqua Water Technologies Announces Pricing of Secondary Public Offering
- Berkshire Hathaway Homeservices Hilton Head Bluffton Realty Taps Christina Galbreath-Gonzalez To Lead Bluffton Office
- Robert T. Ball, Jr., MD Honored with ReadyCommunities Partnership/CCROA 2020 National Service Award For Leadership in SC Communities Amidst Pandemic
- Australian Artist seeks 4 Million USD in damages from Bollywood
- Reigning National Football League's DPOY, Stephon Gilmore, Hand Writes a Note to his Five-Year Old Son, Addressing Why "Black Lives Matter"
- A&L Motor Sales Unveils State-of-the-Art Showroom for Jaguar and Land Rover
- Pennsylvania: Wolf Administration Expands Testing Sites Across the Commonwealth
- A&L Motor Sales Unveils State-of-the-Art Showroom for Jaguar and Land Rover
- Thomas'® Celebrates 140 Years of Yum with First-Ever Cookbook
- Clearwater Living Certified as a Great Place to Work®
- American Homebuilders of West Africa Announces further expansion in Guinea
- TripDelivers Announces Today Partnering with Ghost Kitchen Brands of Canada and Ghost Kitchens USA
- Who Inspired Me the Most? Learn what I (Harry Javer) learned from Successful Top Entrepreneurs, Artists, & Celebrities I met with
- TVS Select Network.Com Debuts Nine More Media Storytellers in Zoomed In with David Brunner Show
- NewAge(R) Industries Increases Warehouse Space at Its Southeastern PA Headquarters by 25 Percent
- Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against JOYY Inc. (YY)
- ClimeCoGreen Launches a New Website to Calculate and Reduce Your Carbon Footprint